

COMMENTARIES

- 635** Disease Interception: Myths, Mountains, and Mole Hills
William N. Hait and Peter F. Lebowitz
- 638** Understanding Intratumoral Heterogeneity: Lessons from the Analysis of At-Risk Tissue and Premalignant Lesions in the Colon
Chelsie K. Sievers, Alyssa A. Leystra, Linda Clipson, William F. Dove, and Richard B. Halberg
See Cancer Prev Res 9(6):417-27
- 642** Is There a Future for Chemoprevention of Prostate Cancer?
Maarten C. Bosland

REVIEW: MOLECULAR PATHOGENESIS OF PREMALIGNANCY SERIES

- 648** Premalignancy in Prostate Cancer: Rethinking What we Know
Angelo M. De Marzo, Michael C. Haffner, Tamara L. Lotan, Srinivasan Yegnasubramanian, and William G. Nelson

RESEARCH ARTICLES

- 657** STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma
Noah D. Peyser, Lin Wang, Yan Zeng, Marie Acquafondata, Maria Freilino, Hua Li, Malabika Sen, William E. Gooding, Masanobu Satake, Zhenghe Wang, Daniel E. Johnson, and Jennifer R. Grandis
- 664** Plasma 25-Hydroxyvitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer in the Nurses' Health Study
Mingyang Song, Gauree Gupta Konijeti, Chen Yuan, Ashwin N. Ananthakrishnan, Shuji Ogino, Charles S. Fuchs, Edward L. Giovannucci, Kimmie Ng, and Andrew T. Chan

- 673** Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk
Vered Steams, Mary Jo Fackler, Sidra Hafeez, Zoila Lopez Bujanda, Robert T. Chatterton, Lisa K. Jacobs, Nagi F. Khouri, David Ivancic, Kara Kenney, Christina Shehata, Stacie C. Jeter, Judith A. Wolfman, Carola M. Zalles, Peng Huang, Seema A. Khan, and Saraswati Sukumar
- 683** A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia
Moni Abraham Kuriakose, Kunnambath Ramdas, Bindu Dey, Subramanya Iyer, Gunaseelan Rajan, Kalavathy K. Elango, Amritha Suresh, Divya Ravindran, Rajneesh R. Kumar, Prathiba R, Surya Ramachandran, Nisha Asok Kumar, Gigi Thomas, Thara Somanathan, Hiran K. Ravindran, Kannan Ranganathan, Sudhakar Babu Katakam, Shivashankar Parashuram, Vijayvel Jayaprakash, and M. Radhakrishna Pillai
- 692** Effects of Walnut Consumption on Colon Carcinogenesis and Microbial Community Structure
Masako Nakanishi, Yanfei Chen, Veneta Qendro, Shingo Miyamoto, Erica Weinstock, George M. Weinstock, and Daniel W. Rosenberg
- 704** Effects of Black Raspberry Extract and Protocatechuic Acid on Carcinogen-DNA Adducts and Mutagenesis, and Oxidative Stress in Rat and Human Oral Cells
Joseph B. Guttenplan, Kun-Ming Chen, Yuan-Wan Sun, Wieslawa Kosinska, Ying Zhou, Seungjin (Agatha) Kim, Youngjae Sung, Krishne Gowda, Shantu Amin, Gary D. Stoner, and Karam El-Bayoumy

Table of Contents

ABOUT THE COVER

The cover image shows a region (taken at approximately 200× magnification) of invasive prostatic adenocarcinoma glands infiltrating the prostatic stroma amongst benign/normal appearing prostatic glands/acini. Shown is an immunohistochemical stain against ERG (brown staining), which stains the tumor cell nuclei (indicated by arrows). Blue staining shows nuclei counterstained with hematoxylin. Note that benign endothelial cells are also positive for ERG (not specifically pointed out in the figure but apparent in the stroma as small nuclei with very strong intensity staining for ERG). Arrowheads show ERG positive adenocarcinoma cells partially replacing epithelium in benign acini/ducts. Four such partially involved benign glands are shown (denoted by numerals 1–4). These findings are supportive of the concept of retrograde colonization of benign/normal appearing acini/ducts by prostatic adenocarcinoma cells. It is expected that the tumor cells partially filling these acini/ducts may commonly undergo expansion over time to fully replace the benign epithelial cells. It is evident, therefore, that this spreading of invasive adenocarcinoma cells, which generally do have the appearance of malignant appearing cells on standard hematoxylin and eosin stained slides, into benign acini/ducts could lead to a misclassification of what is actually invasive adenocarcinoma as high grade PIN. See article by De Marzo et al. (beginning on page 648) for more information.

